Clinical Trial Detail

NCT ID NCT01806064
Title A Phase 1B Dose-escalation Study of TRC105 in Combination With Axitinib in Patients With Advanced Renal Cell Carcinoma
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors Tracon Pharmaceuticals Inc.
Indications

renal cell carcinoma

Therapies

Bevacizumab + Carotuximab

Age Groups: adult

No variant requirements are available.